Trial Profile
Phase II study of FOLFIRI+Ramucirumab with early recurrent colorectal cancer refractory to adjuvant chemotherapy with oxaliplatin / fluoropyrimidine(RAINCLOUD)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 20 Aug 2022
Price :
$35
*
At a glance
- Drugs Ramucirumab (Primary) ; Fluorouracil; Folinic acid; Irinotecan
- Indications Colorectal cancer
- Focus Therapeutic Use
- Acronyms RAINCLOUD
- 02 Jul 2022 Primary endpoint (Progression-Free Survival (PFS)) has been met, according to Results presented at the 24th World Congress on Gastrointestinal Cancer .
- 02 Jul 2022 Status changed from recruiting to completed, according to Results presented at the 24th World Congress on Gastrointestinal Cancer .
- 02 Jul 2022 Results presented at the 24th World Congress on Gastrointestinal Cancer